Antibody-cytokine fusion proteins for treatment of cancer: Engineering cytokines for improved efficacy and safety

Seminars in Oncology

Volumn 41, Issue 5, 2014, Pages 623-636

  Young, Patricia A ^a   Morrison, Sherie L ^a   Timmerman, John M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BC1 INTERLEUKIN 12 FUSION PROTEIN; BETA INTERFERON; DEIMMUNIZED LEUCINE 16 INTERLEUKIN 2 FUSION PROTEIN; EMD 273063; GAMMA INTERFERON; HYBRID PROTEIN; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 21; L19 GAMMA INTERFERON FUSION PROTEIN; L19 INTERLEUKIN 2 FUSION PROTEIN; L19 TUMOR NECROSIS FACTOR ALPHA FUSION PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20 INTERFERON ALPHA FUSION PROTEIN; MONOCLONAL ANTIBODY CD20 INTERLEUKIN 21 FUSION PROTEIN; RECOMBINANT ANTIBODY; RECOMBINANT ANTIBODY CYTOKINE FUSION PROTEIN; RECOMBINANT CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VELTUZUMAB HUMAN INTERFERON ALPHA 2B FUSION PROTEIN; CYTOKINE;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CAPILLARY LEAK SYNDROME; CHILL; COLORECTAL CANCER; CYTOPENIA; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEVER; FLU LIKE SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; HYPOXIA; IMMUNE RESPONSE; IMMUNOSTIMULATION; INJECTION SITE REACTION; KIDNEY CARCINOMA; KIDNEY FAILURE; LARGE CELL LYMPHOMA; MALAISE; MANTLE CELL LYMPHOMA; MELANOMA; MENTAL DISEASE; METASTATIC MELANOMA; NAUSEA; NEUROBLASTOMA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN ENGINEERING; SIDE EFFECT; SOLID TUMOR; TECHNOLOGY; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VASCULAR LEAK SYNDROME; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; SAFETY;

ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; SAFETY;

EID: 84909581250     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.08.002     Document Type: Article

References (67)

1. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother. 2001;24(5):392-407.
2. Fewkes NM, Mackall CL. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J. 2010;16(4):392-8.
3. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6(1):34-55.
4. Lechner MG, Russell SM, Bass RS, et al. Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy. 2011;3(11):1317-40.
5. Penichet ML, Morrison SL. Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods. 2001;248(1-2):91-101.
6. Helguera G, Morrison SL, Penichet ML. Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy. Clin Immunol. 2002;105(3):233-46.
7. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8-32.
8. Grimley PM, Fang H, Rui H, et al. Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-alpha. Blood. 1998;91 (8):3017-27.
9. Yanase N, Ohshima K, Ikegami H, et al. Cytochrome c release, mitochondrial membrane depolarization, caspase-3 activation, and Bax-alpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells. J Interferon Cytokine Res. 2000;20(12):1121-9.
10. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003;8(3):237-49.
11. Heslop HE, Bianchi AC, Cordingley FT, et al. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med. 1990;172 (6):1729-34.
12. Einat M, Resnitzky D, Kimchi A. Close link between reduction of C-myc expression by interferon and G0/G1 arrest. Nature. 1985;313(6003):597-600.
13. Xu D, Erickson S, Szeps M, et al. Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood. 2000;96(13):4313-8.
14. Oehadian A, Koide N, Mu MM, et al. Interferon (IFN)-beta induces apoptotic cell death in DHL-4 diffuse large B cell lymphoma cells through tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cancer Lett. 2005;225:85-92.
15. Borden EC. Milstein Award Lecture: Interferons and cancer: where from here? J Interferon Cytokine Res. 2005;25(9):511-27.
16. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nature Rev Drug Disc. 2007;6(12):975-90.
17. Bekisz J, Baron S, Balinsky C, et al. Antiproliferative properties of type I and type II interferon. Pharmaceuticals (Basel). 2010;3(4):994-1015.
18. Quesada JR, Alexanian R, Kurzrock R, et al. Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia. Am J Hematol. 1988;29(1):1-4.
19. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer-cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316(15):889-97.
20. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal-cell cancer using high-dose bolus interleukin-2. JAMA. 1994;907-13.
21. Lotze MT, Frana LW, Sharrow SO, et al. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol. 1985;134 (1):157-66.
22. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180-90.
23. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33(2):153-65.
24. Kontermann RE. Antibody-cytokine fusion proteins. Arch Biochem Biophys. 2012;526(2):194-205.
25. Suzuki K, Aoki K, Ohnami S, et al. Adenovirus-mediated gene transfer of interferon alpha improves dimethylnitrosamine-induced liver cirrhosis in rat model. Gene Ther. 2003;10(9):765-73.
26. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317-27.
27. Timmerman JM, Byrd JC, Andorsky DJ, et al. A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res. 2012;18(20):5752-60.
28. Ruegg C, Yilmaz A, Bieler G, et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med. 1998;4(4):408-14.
29. List T, Neri D. Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol. 2013;5:29-45.
30. Mujoo K, Cheresh DA, Yang HM, et al. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987;47 (4):1098-104.
31. Becker JC, Pancook JD, Gillies SD, et al. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci U S A. 1996;93(7):2702-7.
32. Albertini MR, Hank JA, Gadbaw B, et al. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunol Immunother. 2012;61(12):2261-71.
33. Shusterman S, London WB, Gillies SD, et al. Antitumor activity of Hu14.18-IL2 in patients with relapsed/ refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010;28(33):4969-75.
34. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359(6):613-26.
35. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47(2):115-23.
36. Gillies SD, Lan Y, Williams S, et al. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood. 2005;105(10):3972-8.
37. Fowler N, Younes A. There will be blood: targeting tumor vasculature. Blood. 2009;113(10):2121-2.
38. Schliemann C, Palumbo A, Zuberbuhler K, et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood. 2009;113(10):2275-83.
39. Eigentler TK, Weide B, de Braud F, et al. A doseescalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res. 2011;17(24):7732-42.
40. Johannsen M, Spitaleri G, Curigliano G, et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer. 2010;46(16):2926-35.
41. Sarosiek KA, Malumbres R, Nechushtan H, et al. Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood. 2010;115(3):570-80.
42. Bhatt S, Zhu D, XJiang X, et al. Targeting B-cell malignancies with anti-CD20-interleukin-21 fusokine. Blood. 2013;122:377.
43. Pegram HJ, Chekmasova AA, Gavin H. AAC, Imperato GH, Brentjens RJ. Interleukin 12: stumbling blocks and stepping stones to effective anti-tumor therapy. In: Arnouk H, ed: Advancements in tumor immunotherapy and cancer vaccines. 2010; InTech, DOI: 10.5772/30084. Available from: http://www.intechopen.com/books/advancements-in-tumor-immunotherapy-and-cancer-vaccines/interleukin-12-stumbling-blocks-and-stepping-stones-to-effective-anti-tumor-therapy.
44. Lo KM, Lan Y, Lauder S, et al. huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Cancer Immunol Immunother. 2007;56 (4):447-57.
45. Rudman SM, Jameson MB, McKeage MJ, et al. A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011;17(7):1998-2005.
46. Borsi L, Balza E, Carnemolla B, et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood. 2003;102(13):4384-92.
47. Spitaleri G, Berardi R, Pierantoni C, et al. Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. J Cancer Res Clin Oncol. 2013;139(3):447-55.
48. Papadia F, Basso V, Patuzzo R, et al. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J Surg Oncol. 2013;107 (2):173-9.
49. Xuan C, Steward KK, Timmerman JM, et al. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood. 2010;115(14):2864-71.
50. Trinh KR, Vasuthasawat A, Steward KK, et al. Anti- CD20-interferon-beta fusion protein therapy of murine B-cell lymphomas. J Immunother. 2013;36(5):305-18.
51. Yamada RE, Steward KK, Ngarmchamnanrith G, et al. Anti-CD20-interferon-alpha fusion protein has superior in vivo activity against human B-cell lymphomas compared to rituximab and enhanced complementdependent cytotoxicity in vitro. J Clin Oncol. 2013;31(suppl) abstr 3024.
52. Yoo E, Vasuthasawat A, Tran D, et al. Anti-CD138-IFNα fusion proteins are effective in treating multiple myeloma. Blood. 2012;120:939.
53. Yang X, Zhang X, Fu ML, et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell. 2014;25 (1):37-48.
54. Rossi EA, Goldenberg DM, Cardillo TM, et al. CD20- targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. 2009;114(18):3864-71.
55. Marth C, Windbichler GH, Hausmaninger H, et al. Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int J Gynecol Cancer. 2006;16(4):1522-8.
56. Ebbinghaus C, Ronca R, Kaspar M, et al. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer. 2005;116 (2):304-13.
57. Marlind J, Kaspar M, Trachsel E, et al. Antibodymediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res. 2008;14(20):6515-24.
58. Gutbrodt KL, Schliemann C, Giovannoni L, et al. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Translat Med. 2013;5:201.
59. Pedretti M, Verpelli C, Marlind J, et al. Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer. 2010;103 (6):827-36.
60. Laurent J, Touvrey C, Gillessen S, et al. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Translat Med. 2013;11.
61. Gillessen S, Gnad-Vogt US, Gallerani E, et al. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur J Cancer. 2013;49(1):35-44.
62. Kim JW, Heery CR, Bilusic M, et al. First-in-human phase I trial of NHS-IL12 in advanced solid tumors. J Clin Oncol. 2012;30(suppl) abstr TPS2617.
63. Rossi EA, Rossi DL, Cardillo TM, et al. Preclinical studies on targeted delivery of multiple IFNalpha2b to HLA-DR in diverse hematologic cancers. Blood. 2011;118(7):1877-84.
64. Gladkov O, Biakhov M, Ramlau R, et al. Phase II trial of huKS-IL2 with cyclophosphamide (CTX) in patients with extensive disease small-cell lung cancer (EDSCLC). J Clin Oncol. 2012;30(15).
65. Connor JP, Cristea MC, Lewis NL, et al. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. BMC Cancer. 2013;13:20.
66. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64.
67. Schwager K, Hemmerle T, Aebischer D, et al. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol. 2013;133(3):751-8.